Q-omics provides the consensus-scored CAPRIN1 profile across patient tissues and cancer cell-line models. CAPRIN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CAPRIN1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CAPRIN1 protein abundance shows 33,466 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where CAPRIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPRIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPRIN1 survival associations across molecular data types. CAPRIN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPRIN1 RNA expression–survival associations across cancer types. High CAPRIN1 expression shows unfavorable associations in ACC, LIHC, MESO and PAAD, but favorable associations in KIRC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CAPRIN1 RNA expression.
This table summarizes CAPRIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CAPRIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPRIN1 shows higher tumor expression in HNSC, LIHC, STAD, COAD, BLCA and LUAD. The HNSC box plot shows higher CAPRIN1 RNA expression in tumor versus normal tissue (log2 FC = +0.762, t-test p < 0.001).
This table shows molecular features associated with CAPRIN1 in patient tissues and cancer cell lines. In patient samples, CAPRIN1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPRIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and OVARY.
